BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...

The United States is facing a demographic shift as the population of older adults grows rapidly, with the proportion of ...

A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...

For patients with acute coronary syndrome, targeted vitamin D3 supplementation is associated with a reduced risk for follow-up myocardial infarction.

Researchers sought to determine the most appropriate P2Y12 inhibitor therapy in patients with acute coronary syndrome.

The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Prasugrel may be the P2Y12 inhibitor of choice for use in combination with aspirin after PCI in patients with diabetes and ...

Intense emotional pain can trigger broken heart syndrome, a condition that weakens the heart muscle. It mimics heart attack ...

Investing.com -- Bristol Myers Squibb (NYSE:BMY) stock fell 5.2% in premarket trading Friday after the company announced it would discontinue its Phase 3 Librexia ACS trial for milvexian in acute ...

How bad will this year’s flu season be in the United States? At the moment, we have no answer to that important question.